In a new study, the diabetes drug rosiglitazone was not associated with an increased risk of major cardiovascular events and mortality in diabetic patients who had established CAD….
Read More »Fruit Restriction for Type 2’s: Good or Not?
Danish hospital researchers show that the recommendation among conventional doctors and nutritionists to type 2 diabetes patients to lay off the fruit may be wrong….
Read More »Health Assessments Decrease Incidence of Diabetes, CVD
Regular health assessments would reduce the incidence of diabetes and cardiovascular disease, and would also be cost-effective….
Read More »Red Wine Supplement Can Block Benefits of Exercise
Resveratrol prevented gains in blood pressure, cholesterol and aerobic fitness….
Read More »SNARE Proteins Could Hold Secret to Treating Type 2 Diabetes
Scientists believe the proteins that are targeted by cosmetic surgery treatment could hold the secret to treating and even curing type 2 diabetes….
Read More »Some Countries Paying Patients in Gold to Lose Weight
The cost of obesity and diabetes has gotten so high and the epidemic is growing so fast that now Dubai is paying gold to patients who lose weight….
Read More »Hemoglobinopathies May Distort HbA1C – A Caution to Practitioners
Measuring glycated hemoglobin (HbA1c) gives us a patient’s long term average blood glucose levels.1 Since HbA1c measures the percentage of patients’ glycosolated hemoglobin, patients who possess variants of hemoglobin can exhibit false readings. Such variants, called hemoglobinopathies, can include inherited hemoglobin variants, elevated fetal hemoglobin, and hemoglobin S and E …
Read More »FDA Issues Letters to Companies Promoting Illegal Diabetes Treatments
Fifteen companies were warned about selling products with false advertising….
Read More »Long Term Complications in Young-Onset Type 1 and Type 2 Diabetes
Young-onset type 2 diabetes patients have a greater mortality and lethality when compared to type 1 diabetes in similar ages of onset….
Read More »Sitagliptin in Type 2 Diabetes: Great Safety and Tolerability
A new pooled analysis shows DPP-4 inhibitors have a greater safety and tolerability profile when compared to other antihyperglycemic agents….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.